| T76858 |
Ascrinvacumab
|
1463459-96-2
|
98%
|
Ascrinvacumab
|
|
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ...
|
| T35694 |
OD36
|
1638644-62-8
|
98%
|
|
|
OD36 is a selective and potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 inhibits ALK2 signaling and osteogenic differentiation (KD: 37 nM), and binds efficien...
|
| T2641 |
KRCA-0008
|
1472795-20-2
|
|
|
|
KRCA-0008 is an effective and specific ALK/Ack1 inhibitor (IC50: 12/4 nM); displays drug-like properties without hERG liability.
|
| T5197 |
BIBF0775
|
334951-90-5
|
|
|
|
BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).
|
| T2612 |
CEP-28122
|
1022958-60-6
|
|
|
|
CEP-28122 is a highly potent and selective orally active ALK inhibitor.
|
| T1936 |
Alectinib
|
1256580-46-7
|
|
|
|
Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
|
| T6158 |
LDN-193189 HCl
|
1062368-62-0
|
100%
|
|
|
LDN-193189 HCl (LDN193189 Hydrochloride) is a selective BMP type I receptor kinases inhibitor.
|
| T3621 |
Brigatinib
|
1197953-54-0
|
100%
|
|
|
Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor.
|
| T50042 |
5-phenylthieno[2,3-d]pyrimidin-4-amine
|
195193-10-3
|
95.00%
|
|
|
5-phenylthieno[2,3-d]pyrimidin-4-amine is a heterocyclic compound. It inhibits a variety of enzymes such as kinases and phosphodiesterases and has potential ther...
|
| T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
| T11254 |
F-1
|
2244775-31-1
|
97.66%
|
|
|
F-1 is IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 is a potent ALK and ROS1 dual inhibitor, suppress...
|
| T3059 |
ALK-IN-1
|
1197958-12-5
|
97.66%
|
|
|
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M ...
|
| T1962 |
ASP3026
|
1097917-15-1
|
98%
|
|
|
ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Posit...
|
| T1800 |
GW788388
|
452342-67-5
|
98%
|
|
|
GW788388 is a potent and selective inhibitor of ALK5, also inhibits TGF-(beta) type II receptor and activin type II receptor activities.
|
| T15612 |
JH-VIII-157-02
|
1639422-97-1
|
98.02%
|
|
|
JH-VIII-157-02 is an inhibitor of ALK and inhibits echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) with IC50s of 2 nM for EML4-ALK G1202R, EML4-A...
|
| T15572 |
IN-1130
|
868612-83-3
|
98.08%
|
|
|
IN-1130 is a selective inhibitor of ALK5 with IC50 values of 5.3 nM, 36 nM, and 4.3 μM for phosphorylation of ALK5-mediated Smad3, ALK5 phosphorylation of casein...
|
| T35896 |
AZ 12799734
|
1117684-36-2
|
98.23%
|
|
|
AZ 12799734 is an orally active, selective and potent dual inhibitor of TGFBR1 and ALK5 with inhibitory effects on BMP and TGFβ for the study of tumours.
|
| T1943 |
ML347
|
1062368-49-3
|
98.3%
|
|
|
ML347 (LDN 193719)(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
|
| T9224 |
CH5424802 analog
|
1256577-71-5
|
98.31%
|
|
|
CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
|
| T13416 |
ZX-29
|
2254805-62-2
|
98.32%
|
|
|
ZX-29 is a potent and selective inhibitor of ALK(IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively), and also induces ...
|
